STAT 解读 Isomorphic Labs：高估值背后的 AI 制药争论
STAT+: What’s the deal with Isomorphic Labs?
精选理由
AlphaFold 团队分拆的 Isomorphic Labs 估值不低，这期报道把 AI 制药的争议讲清楚了
STAT 的 AI Prognosis 栏目聚焦 AlphaFold 开发团队分拆出的 Isomorphic Labs。这家公司的高估值引发了对 AI 在药物研发中实际作用的讨论。报道同时梳理了围绕 AI 能否降低医疗成本的争议。
原文 · STAT News · Health Tech
STAT+: What’s the deal with Isomorphic Labs?
In this edition of STAT's AI Prognosis: What does Isomorphic Labs' high valuation say about AI's role in drug development, and the debate around AI and cost of care.
